Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Alpha-1a adrenergic receptor | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | References | |
Rattus norvegicus | Opioid receptor | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled | References | |
Rattus norvegicus | Alpha-1b adrenergic receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Muscarinic acetylcholine receptor M3 | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Homo sapiens | sigma non-opioid intracellular receptor 1 | Starlite/ChEMBL | References |
Rattus norvegicus | Glutamate [NMDA] receptor subunit epsilon 3 | Starlite/ChEMBL | References |
Rattus norvegicus | Muscarinic acetylcholine receptor M2 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | p450 reductase, putative | 0.1589 | 1 | 1 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0662 | 0.3417 | 0.3417 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1589 | 1 | 1 |
Mycobacterium tuberculosis | Hypothetical oxidoreductase | 0.0181 | 0 | 0.5 |
Echinococcus granulosus | hypothetical protein | 0.0859 | 0.4816 | 0.4816 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0981 | 0.5684 | 0.5684 |
Mycobacterium tuberculosis | Possible electron transfer protein FdxB | 0.0181 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0608 | 0.3033 | 0.3033 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0662 | 0.3417 | 0.3417 |
Loa Loa (eye worm) | hypothetical protein | 0.0526 | 0.245 | 0.245 |
Treponema pallidum | flavodoxin | 0.0608 | 0.3033 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0608 | 0.3033 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1589 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0801 | 0.4402 | 0.4402 |
Loa Loa (eye worm) | hypothetical protein | 0.1589 | 1 | 1 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0833 | 0.4633 | 0.4633 |
Loa Loa (eye worm) | hypothetical protein | 0.0526 | 0.245 | 0.245 |
Leishmania major | cytochrome P450 reductase, putative | 0.1409 | 0.8717 | 0.8717 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1409 | 0.8717 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0608 | 0.3033 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1589 | 1 | 1 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0608 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | hypothetical protein | 0.0227 | 0.0331 | 0.0331 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0789 | 0.4316 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0789 | 0.4316 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.1409 | 0.8717 | 0.8717 |
Brugia malayi | Serotonin receptor | 0.0581 | 0.2844 | 0.2844 |
Chlamydia trachomatis | sulfite reductase | 0.0981 | 0.5684 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1589 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1589 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1589 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0981 | 0.5684 | 0.5684 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0608 | 0.3033 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1589 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0981 | 0.5684 | 0.5684 |
Brugia malayi | FAD binding domain containing protein | 0.1589 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1589 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1589 | 1 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0608 | 0.3033 | 0.3033 |
Brugia malayi | flavodoxin family protein | 0.0608 | 0.3033 | 0.3033 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0789 | 0.4316 | 0.4316 |
Mycobacterium tuberculosis | Possible oxygenase | 0.0181 | 0 | 0.5 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0608 | 0.3033 | 0.3033 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0608 | 0.3033 | 0.3033 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1589 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0608 | 0.3033 | 0.5 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0662 | 0.3417 | 0.3417 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0608 | 0.3033 | 0.3033 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1589 | 1 | 1 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0608 | 0.3033 | 0.3033 |
Plasmodium vivax | hypothetical protein, conserved | 0.0608 | 0.3033 | 0.3033 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1589 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.1589 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0608 | 0.3033 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1589 | 1 | 1 |
Schistosoma mansoni | amine GPCR | 0.0226 | 0.032 | 0.032 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0608 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | hypothetical protein | 0.0662 | 0.3417 | 0.3417 |
Echinococcus granulosus | methionine synthase reductase | 0.0981 | 0.5684 | 0.5684 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0181 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1589 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1589 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.1409 | 0.8717 | 0.8159 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0662 | 0.3417 | 0.3417 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1589 | 1 | 1 |
Mycobacterium tuberculosis | Probable monooxygenase | 0.0181 | 0 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1589 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1589 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1409 | 0.8717 | 1 |
Onchocerca volvulus | 0.0181 | 0 | 0.5 | |
Echinococcus multilocularis | methionine synthase reductase | 0.0981 | 0.5684 | 0.5684 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 9.21 | Displacement of [3H](+)-pentazocine from sigma1 receptor in human Jurkat cell membrane | ChEMBL. | 20067271 |
Ki (binding) | = 0.62 nM | Compound was tested for its binding affinity towards sigma 1 receptor using [3H]-(+)-pentazocine from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | = 0.62 nM | Compound was tested for its binding affinity towards sigma 1 receptor using [3H]-(+)-pentazocine from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | = 22 nM | Binding affinity towards sigma 2 receptor using [3H]-DTG in the presence of 200 nM (+)-NANM from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin from guinea pig frontal cortex | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Dopamine receptor D2 using [3H]-spiperone from rat striatum | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1A adrenergic receptor using [3H]-prazosin from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1B adrenergic receptor using [3H]-prazosin from rat liver | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M2 using [3H]-NMS from rat heart | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M3 using [3H]-NMS from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Opioid receptors using [3H]-naloxone from rat whole brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards PCP receptor using [3H]-(+)-NANM in the presence of 5 microM haloperidol from rat brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin from guinea pig frontal cortex | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Dopamine receptor D2 using [3H]-spiperone from rat striatum | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1A adrenergic receptor using [3H]-prazosin from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1B adrenergic receptor using [3H]-prazosin from rat liver | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M2 using [3H]-NMS from rat heart | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M3 using [3H]-NMS from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Opioid receptors using [3H]-naloxone from rat whole brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards PCP receptor using [3H]-(+)-NANM in the presence of 5 microM haloperidol from rat brain | ChEMBL. | 9572880 |
Selectivity (binding) | = 35 | Selectivity for sigma 2 receptor and sigma 1 receptor from guinea pig brain was evaluated | ChEMBL. | 9572880 |
Selectivity (binding) | = 35 | Selectivity for sigma 2 receptor and sigma 1 receptor from guinea pig brain was evaluated | ChEMBL. | 9572880 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.